Bortezomib

Bortezomib

Saved in:

Bibliographic Details
Main Author:	Rajappa Senthil
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2010-12-01
Series:	Indian Journal of Medical and Paediatric Oncology
Online Access:	http://www.ijmpo.org/article.asp?issn=0971-5851;year=2010;volume=31;issue=4;spage=143;epage=144;aulast=Rajappa
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bortezomib in Kidney Transplantation
by: Rajeev Raghavan, et al.
Published: (2010-01-01)

Bortezomib Induced Hepatitis B Reactivation
by: Salwa Hussain, et al.
Published: (2014-01-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Successful Use of Bortezomib in an Adolescent with Refractory TTP
by: Junaid Ahmad Wali, et al.
Published: (2023-01-01)

Fluorous-tagged bortezomib supramolecular nanomedicine for cancer therapy
by: Changping Wang, et al.
Published: (2024-12-01)

Intestinal Perforation Secondary to Bortezomib‐Induced Autonomic Neuropathy
by: Jose Antonio Sánchez Salas, et al.
Published: (2025-04-01)

Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance
by: Holly Lee, et al.
Published: (2019-01-01)

Drug repurposing: Bortezomib in the treatment of PTEN‐deficient iCCA
by: Shi‐jia Dai, et al.
Published: (2024-12-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
by: Dan Xie, et al.
Published: (2025-02-01)

Clinical use and toxicities of bortezomib in pediatric patients: a systematic review
by: Zachary C. LeBlanc, et al.
Published: (2025-08-01)

Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report
by: Magdalena Klanova, et al.
Published: (2012-01-01)

Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cells
by: Grażyna Świderska-Kołacz, et al.
Published: (2025-04-01)

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
by: Vania dos Santos Nunes-Nogueira, et al.
Published: (2022-06-01)

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome
by: Hua Bai, et al.
Published: (2025-01-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
by: V. A. Misyurin, et al.
Published: (2019-01-01)

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States.
by: Amanda M DiNofia, et al.
Published: (2016-01-01)

Successful treatment with bortezomib for POEMS syndrome, overcoming complicated severe heart block
by: Yuichi Nakamura, et al.
Published: (2023-03-01)

Bortezomib induces Rho-dependent hyperpermeability of endothelial cells synergistically with inflammatory mediators
by: Shunichi Nishima, et al.
Published: (2024-12-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
by: Alhasan Elghouche, et al.
Published: (2016-01-01)

Bortezomib and quercetin as effective modulators of lipopolysaccharide-induced systemic inflammatory response and metabolic disorders
by: Ye. O. Morhun, et al.
Published: (2025-06-01)

The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia
by: Camila Terreros-Palacios, et al.
Published: (2025-07-01)

Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy
by: Li-Jun Xue, et al.
Published: (2010-01-01)

Structural Insights into Bortezomib-Induced Activation of the Caseinolytic Chaperone-Protease System in Mycobacterium tuberculosis
by: Biao Zhou, et al.
Published: (2025-04-01)

Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma
by: Mingyuan Jia, et al.
Published: (2025-04-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

The importance of preexisting drug resistance due to overexpression of P-glycoprotein for the formation of resistance to bortezomib
by: L. A. Laletina, et al.
Published: (2020-03-01)

Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
by: E. Z. Irugova, et al.
Published: (2025-03-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Role of TRIM24 in the regulation of proteasome-autophagy crosstalk in bortezomib-resistant mantle cell lymphoma
by: Corentin Bouvier, et al.
Published: (2025-03-01)

Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis.
by: Yi Xiao, et al.
Published: (2014-01-01)